Rock Springs Capital Management LP Athira Pharma, Inc. Transaction History

Rock Springs Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.74 - $13.43 $1.51 Million - $7.42 Million	-552,252 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$9.15 - $11.09 $1.79 Million - $2.17 Million	-195,950 Reduced 26.19%	552,252 $5.18 Million
Q2 2021 Aug 16, 2021	SELL	$10.24 - $20.87 $409,600 - $834,800	-40,000 Reduced 5.07%	748,202 $7.66 Million
Q1 2021 May 17, 2021	SELL	$16.9 - $29.77 $1.23 Million - $2.16 Million	-72,700 Reduced 8.44%	788,202 $14.5 Million
Q4 2020 Feb 16, 2021	SELL	$16.48 - $34.3 $3.98 Million - $8.29 Million	-241,800 Reduced 21.93%	860,902 $29.5 Million
Q3 2020 Nov 16, 2020	BUY	$16.02 - $18.46 $17.7 Million - $20.4 Million	1,102,702 New	1,102,702 $20.4 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $25.3M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.